Kemal Yelekçi, TÜBİTAK-1001 2015S009 “Development of Novel Synthetic Agents for Prostate Cancer Treatment.” Researcher (2016-2020)
Şebnem Eşsiz Gökhan, TÜBİTAK 115S387 Novel azole compounds with potential antifungal and anticonvulsant effects: Molecular modeling, synthesis and biological activity research. Researcher (2016-2017)
Kemal Yelekçi, COST Action. (CM1406) “Epigenetic Chemical Biology (EPICHEM)”. Member. (2015-2018)
Şebnem Eşsiz Gökhan, TÜBİTAK-3501 . “The working mechanism for NMDA type receptors and the interaction with open ion channel inhibitors”. Project Director (2015-2017)
E. Demet Akten Akdoğan, TÜBİTAK-1001 (213M544). “Investigating the Allosteric Mechanism in β2 Adrenergic Receptor upon Activation/Inactivation and its Application in Drug Design”. Project Director. (2014-2016)
Kemal Yelekçi, FP7. Marie Curie Initial Training Networks (ITN). Call: FP7-PEOPLE-2013-ITN. Project ID: 608381. “Training in Neurodegeneration, Therapeutics Intervention & Neurorepair – TINTIN”. Project member. (2013-2017)
E. Demet Akten Akdoğan, TÜBİTAK-1001 (113M237). “New computational approaches to unravel allosteric mechanisms and ligand binding sites”. Researcher. (Project Director: Prof. Pemra Doruker Turgut) (2013-2016)
Cem Özen, TÜBİTAK-1001 . “Calculation of Nuclear Spin Distributions Using A Microscopic Model, principal investigator”: (2013-2016).
Kemal Yelekçi, İSTKA. “Establishment of Networking between Academia and Drug Companies and organization of a new Technology Center for a novel drug discovery, development and knowledge sharing- İlaç Temel Araştırma Merkezi – İTAM”. Project member. (2012-2013)
Kemal Yelekçi, COST Action CM1103. “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”. Member. (2011-2015)
Kemal Yelekçi, TÜBİTAK-TBAG 211T100. “In Silico Design of Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors in Order to Prevent Neurodegenerative Diseases”. Project Director. (2012-2013)
Cem Özen, Kadir Has University BAP. “Acceleration of Monte Carlo Algorithms on Graphical processing Units”, principal investigator (2011-2013).
Cem Özen, TÜBİTAK-1001 “Calculation of Parity-dependent Nuclear Level Densities in a Quantum Monte Carlo Approach”, (2010-2012).
E. Demet Akten Akdoğan, TÜBİTAK 1001 Project no: 109M281, “Exploring the Dynamic Structure of β2 Adrenergic Receptor and its Importance in Computer-Aided Drug Design”. Project Director (2009-2012)
E. Demet Akten Akdoğan, TÜBİTAK 1001 Project no: 109M213, “Development and application of hybrid algorithms for studying protein flexibility and conformational transitions” (2009-2012)
Şebnem Eşsiz Gökhan, US Department of Energy, LLNL Grant #12-SI-004. Biological Science and Biotechnology, LLNL, CA, USA. “Agonist and antagonist binding on Gamma-Aminobutyric acid(GABA) receptors. Free energy analysis of carbonic anhydrase binding site biomimetic. Acetylcholine Estarase Docking Studies.” Researcher. (2011 – 2012)
E. Demet Akten Akdoğan, Boğaziçi University, Polymer Research Center, “Effects of protein dynamics in computer-aided drug design”. Researcher, (2008)
Kemal Yelekçi, TÜBİTAK 1007 (105G01) . “Drug research and development for hereditary diseases caused by erroneous RNA splicing”. Researcher (2006-2009)
Kemal Yelekçi, FP6-MOBILITY. “Characterisation of Mitochondrial Proteins in Brain”. Researcher. (2006-2010)
Kemal Yelekçi, TÜBİTAK-TBAG 108T232 “Design of new pyrazoline derivatives using molecular modelling; synthesis and determination of their inhibition kinetics by computational and experimental techniques”. Principal investigator. (2008-2010)
Şebnem Eşsiz Gökhan, UCSF, CA, USA. Bioengineering and Theuropatical Science, “Genetic Algorithm based integrative protein structure modeling. Application of graph theory for a “divide-conquer” approach on homology modeling”. Researcher. (Project Director: Prof. Andrej Sali)(2009 – 2011)
Hatice Bahar Şahin, TÜBİTAK 2218 Post-doc grant. “The Role SIK3 Gene in Animal Development and Tumorigenesis”. Researcher. (2011-2013)